Slide 1: Preliminary Results for the year ended 30 April 2016
Preliminary Results for the year ended 30 April 2016 Established Research Use Sales and progressed first clinical application in ovarian cancer Andrew Newland & Ian Griffiths 28 July 2016
Slide 2: Legal disclaimer
Legal disclaimer LSE AIM: AGL OTCQX: ANPCY This presentation has been prepared by ANGLE plc (the “Company”). By attending this presentation and/or reviewing the slides you agree to be bound by the following conditions. The information and opinions contained in this presentation have not been indepen
Slide 3: Highlights
Highlights Liquid Biopsy: Cells for Precision Medicine First sales achieved Analytical and clinical studies developed for FDA clearance Ovarian cancer clinical studies started Growing body of published evidence from third party cancer centres Strengthened IP position with patents granted out to 2034
Slide 4: Financial Results for the year ended April 2016
Financial Results for the year ended 30 April 2016 2016 2015 Statement of Comprehensive Income £’000 £’000 Revenue 361 0 Cost of sales (107) 0 Comments Gross profit 254 0 First sales achieved during Operating costs (5,703) (3,878) the year Other income 22 9 Loss before tax from continuing Geomerics
Slide 5: Precision medicine: Right drug for the right patient at the right time
Precision medicine: Right drug for the right patient at the right time Cancer Research UK: “One in two people born after 1960 in the UK will be diagnosed with some form of cancer during their lifetime.” Each patient’s cancer is different Major pharma developing more selective drugs: Patient’s cancer
Slide 6: Parsortix and the advantages of CTCs for liquid biopsy
ParsortixTM and the advantages of CTCs for liquid biopsy Solid tissue biopsy Liquid biopsy Source Primary tumor Metastatic site CTCs cfDNA Sample type Intact cells Intact cells Intact cells Fragmented DNA Procedure Invasive Invasive Non‐invasive Non‐invasive Sample accessibility Not always accessibl
Slide 7: ANGLE's patented Parsortix system
ANGLE’s patented Parsortix system Stepped, microscale cell Granted patents: US, Europe, Manufactured under ISO13485 separators for fluid flow China, Canada, Australia quality control system and cell separation Patent expiry: 2023 to 2034 European CE mark © ANGLE plc 2016 Page 7
Slide 8: Far-reaching market potential
Far-reaching market potential © ANGLE plc 2016 Page 8
Slide 9: Growing research use sales
Growing research use sales Maiden sales achieved during the year Sales to multiple customers: − existing key opinion leaders transitioning to paying customers − leading cancer research centres − big pharma and immunotherapy companies − repeat customers and multiple instrument orders − first customer
Slide 10: FDA authorisation progress
FDA authorisation progress Seeking to be first FDA cleared system for harvesting cancer cells from blood FDA clearance of the system first for metastatic breast cancer with ovarian cancer and other cancer types to follow − breadth of authorisation to provide flexibility in clinical deployment, allow
Slide 11: Ovarian cancer detection: triaging for pelvic mass surgery
Clinical application Ovarian cancer detection: triaging for pelvic mass surgery Medical University of Vienna Highly successful patient study (n=65) Clinical application in triaging patients − 100% specificity in primary epithelial ovarian with abnormal pelvic mass cancer (no false positives) − to id
Slide 12: Ovarian cancer clinical studies
Clinical application Ovarian cancer clinical studies 200 patient European study in progress (ANG-001) − Medical University of Vienna, Charité - Universitätsmedizin Berlin, Vivantes Klinikum Auguste Viktoria, and Vivantes Hospital Neukölln − target completion end CY16 200 patient United States study
Slide 13: Non-invasive metastatic breast cancer biopsy
Clinical application under consideration Non-invasive metastatic breast cancer biopsy Non-invasive, repeatable, lower cost, more effective Larger study to replicate the RNA-Seq comparison between biopsy of metastatic site and Parsortix liquid biopsy Multiple commercial opportunities − repeat biopsy
Slide 14: Non-invasive prostate biopsy
Clinical application under consideration Non-invasive prostate biopsy Barts Cancer Institute new results − detected 100% of the metastatic prostate − number of mesenchymal CTCs good cancer patients (n=52) correlation to Gleason score − detected 75% early stage including “active − metastatic or local
Slide 15: How ANGLE intends to secure its market position
How ANGLE intends to secure its market position Build research use sales − pipeline growing becoming system of choice Secure Level 1 data − ANG-001 and ANG-003 clinical studies − ANG-002 FDA studies Secure FDA clearance − extensive work in progress − first mover opportunity Prove ovarian cancer clin
Slide 16: Summary
Summary Liquid biopsy ParsortixTM patented system changing the paradigm in an emerging $ multi- billion market High performance in ovarian, prostate, and breast cancers Growing research use sales with a clear competitive advantage CE Mark for indicated clinical use. FDA clearance in process Ovarian
Slide 17: Contact details
Contact details Andrew Newland ANGLE plc 3 Frederick Sanger Road 3711 Market Street The Surrey Research Park University Science Center 8th floor Guildford GU2 7YD Philadelphia PA 19104 United Kingdom USA Tel: +44 1483 685830 +1 (267) 265 6761 Email: andrew.newland@ANGLEplc.com © ANGLE plc 2016 Page